<DOC>
	<DOCNO>NCT02517684</DOCNO>
	<brief_summary>The purpose study determine whether top-down treatment approach , prescribe infliximab ( IFX ) azathioprine ( AZA ) diagnose , yield well outcome comparison usual step-up treatment approach , start prednison AZA exclusive enteral nutrition ( EEN ) AZA , moderate-to-severe pediatric Crohn 's disease ( CD ) patient .</brief_summary>
	<brief_title>Top-down Infliximab Study Kids With Crohn 's Disease</brief_title>
	<detailed_description>Objective : The purpose study determine whether top-down treatment approach , prescribe IFX AZA diagnose , yield well outcome comparison usual step-up treatment approach , start prednison AZA EEN AZA , moderate-to-severe pediatric CD patient . Sample size : We include 100 ( 2 x 50 ) patient . With number difference 60 % 85 % ( = 25 ) show power 80 % ( 2-sided Î± 0.05 ) . Study design : international open-label randomise control trial Study population : Children ( age 3-17 yr ) new-onset , untreated , CD moderate-to-severe disease activity ( weighted Pediatric CD Index [ wPCDAI ] &gt; 40 ) Intervention : Patients randomise either top-down conventional step-up treatment . Treatment arm 1 : Top-down IFX treatment consist total 5 IFX infusion 5 mg/kg ( IFX induction week 0 , 2 6 , follow 2 maintenance infusion every 8 week ) combine oral AZA 2-3 mg/kg daily . AZA therapy continue last IFX infusion maintain remission . Treatment arm 2 : Step-up treatment consist standard induction treatment either oral prednisolone 1 mg/kg ( maximum 40 mg ) daily 4 week , follow taper 6 week stop , EEN polymeric feed 6-8 week normal food gradually reintroduce within 2-3 week . Either induction treatment combine oral AZA 2-3 mg , daily , maintenance treatment . Main study parameters/endpoints : Clinical remission 52 week without need additional CD relate therapy surgery . Secondary endpoint include clinical response , remission mucosal heal week 10 52 , growth , quality life adverse event .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Children ( age 317 year , male female , weight &gt; 10kg ) newonset , untreated CD moderatetosevere disease activity assess wPCDAI &gt; 40 eligible inclusion diagnosis CD make base Porto criterion Patients follow characteristic exclude : immediate need surgery , symptomatic stenosis stricture bowel due scarring , active perianal fistula , severe comorbidity , severe infection sepsis opportunistic infection , positive stool culture , positive Clostridium difficile assay , positive tuberculin test chest radiograph consistent tuberculosis malignancy , already start CD specific therapy , patient suspect definitive pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Crohn 's disease</keyword>
	<keyword>pediatric</keyword>
	<keyword>infliximab</keyword>
	<keyword>top-down</keyword>
	<keyword>TISKids</keyword>
</DOC>